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LONG-TERM TREATMENT WITH LONG-ACTING
RISPERIDONE
Chue PS1, Devos E2, Duchesne IY3, Leal AR2, Mehnert A3
1University of Alberta, Edmonton, Alberta, Canada; 2SGS
Biopharma SA, Wavre, Belgium; 3Janssen Pharmaceutica NV,
Beerse, Belgium
The novel long-acting injection of risperidone, adminis-
tered once every two weeks, is the ﬁrst long-acting for-
mulation of an atypical antipsychotic.
OBJECTIVE: To document the hospitalization rates in
stable patients with schizophrenia or schizoaffective 
disorder during long-term treatment with intramuscular
injections of long-acting risperidone (25mg or 50mg).
METHODS: Hospitalization information over the past 
3 month period was collected at baseline and every 3
months thereafter as part of a resource use assessment
alongside a 1 year multi-center, open-label study in
patients with schizophrenia or schizoaffective disorder.
RESULTS: Of 397 patients included in the analysis, 301
(76%) were outpatients, while 96 (24%) were hospital-
ized inpatients at baseline. The need for hospitalization
decreased continuously over time during treatment with
long-acting risperidone from 38% (150/397) during the
3 months prior to study entry to 28% (111/396) during
months 1–3, 18% (64/359) during months 4–6, 14%
(42/303) during months 7–9 and 12% (33/281) during
months 10–12. This trend over time was statistically 
signiﬁcant (p < 0.0001; longitudinal data analysis using
generalized estimating equations). As a proxy measure 
for relapse, the 1 year re-hospitalization rate was deﬁned
as the ﬁrst hospitalization for outpatients and a new 
hospitalization after discharge for inpatients at baseline.
Of the inpatients at baseline, 28 patients were not dis-
charged during the study period and did not contribute
to the re-hospitalization analysis. The overall 1 year re-
hospitalization rate was 17.6% (65/369). In outpatients,
the hospitalization rate was 15.9% (48/301), while in
inpatients, the re-hospitalization rate was 25.0% (17/68).
CONCLUSION: The need for hospitalization decreased
continuously and signiﬁcantly over a 1 year period of
treatment with long-acting risperidone. The 1 year re-
hospitalization rate associated with long-acting risperi-
done was low at 17.6%.
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THE DIRECT AND INDIRECT ECONOMIC
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OBJECTIVE: To quantify the direct and indirect eco-
nomic costs of psychotic disorders to both patients and
caregivers.
METHODS: Data from the Medical Expenditure Panel
Survey (MEPS) consist of extensive survey data from
approximately 25,000 randomly selected US residents
and consist of information on the primary responder and
other household members, including demography, health-
care utilization and cost linked to diagnoses, insurance,
employment, income, and mental and health status.
Patients with a healthcare encounter associated with a
psychotic condition comprised the patient cohort, while
all other responders were controls. Patients’ family
members and family members of other responders com-
prise the caregiver cohort and the controls, respectively.
Multiple regressions were used to explain variation in
direct expenditures and income loss associated with 
psychoses, caregivers, various mental and health status,
and other appropriate controls. Logistic regressions and
multinominal logistic regressions were used for employ-
ment status and mental and overall health status.
RESULTS: Patient cohort included 112 patients with 
a psychotic condition. Caregiver cohort included 213
family members. Average annual expenditure from all
payment sources was $9288 per patient for schizophrenic
disorders, $3062 for affective psychoses, and $5156 for
other psychotic disorders. Annual incremental out-of-
pocket expenses to patient and family members were
$544 for schizophrenic disorders, $583 for affective psy-
choses, and $767 for other psychotic disorders. The
income loss associated with psychoses to the patient
ranged from $3964 to $5500 (P < 0.04). Compared with
excellent mental health, poorer mental health was asso-
ciated with an additional incremental annual income loss.
Psychotic patients were 40% less likely to be employed
full time (P < 0.01), while family members were 25.9%
less likely to have full-time employment (P < 0.01).
CONCLUSIONS: Signiﬁcant economic burden to both
patients and caregivers is associated with psychotic 
disorders and the use of newer atypical antipsychotics
reduces that burden.
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Depression affects between 5% to 10% of the popula-
tion. Although U.S. studies have estimated the burden of
depression, little is known about its impact in Canada.
OBJECTIVE: To estimate the economic burden of depres-
sion in Canada in 2000.
METHOD: The study was prevalence-based. Adults
between the ages of 18 and 64 with any form of 
depression were considered. Direct costs included hospi-
talizations, Emergency Room visits, visits to general prac-
